Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
Date:2/7/2013

ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues increased to $16.5 million, representing growth of 22% versus the previous quarter
  • Gross and net NUEDEXTA® sales increased to $18.4 million and $14.9 million, respectively, representing growth of 19% and 20% versus the previous quarter
  • Cash, cash equivalents, and restricted investments of $59.3 million as of December 31, 2012.
  • "Avanir delivered another strong quarter of growth with record NUEDEXTA sales and prescriptions," said Keith A. Katkin , president and CEO of Avanir.  "In addition, the clinical team has successfully executed our plan to move our next generation asset, AVP-786, through the first stage of the phase I clinical study, with encouraging results. With demonstrated success in the AVP-786 study, we now have two promising assets in clinical development, each of which has broad potential in a number of CNS indications."

    Fiscal 2013 First Quarter Results

  • Total net revenues for the quarter ended December 31, 2012 were $16.5 million, compared with $7.2 million for the comparable quarter in fiscal 2012, representing 130% year-over-year growth. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®.
  • Total operating expenses, excluding cost of sales and share-based compensation were $25.3 million in the first quarter of fiscal 2013, compared with $21.7 million in the comparable period in fiscal 2012.
  • Cash used in operations was $12.7
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Avanir Pharmaceuticals To Present at Three Conferences In May
    2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
    3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
    5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
    6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
    7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
    8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
    9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/21/2014)... DUBLIN, Ohio and MELVILLE, N.Y. ... (NYSE: CAH ), one of the world,s ... (NASDAQ: HSIC ), the world,s largest provider ... animal health and medical practitioners, today announced that the ... provide one of the most comprehensive service and product ...
    (Date:11/21/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced ... will be presenting at the 26 th Annual Piper ... New York . The formal presentation is ... In addition, Mr. Krakauer and Jorgen B. Hansen , ... during the day. An audio webcast will ...
    (Date:11/21/2014)... Nov. 20, 2014  The acceptance of two ... AAGL Global Congress demonstrates continued interest in the ... provide bowel control. One of the abstracts, presented by ... Division Chief of Urogynecology and Reconstructive Pelvic Surgery ... Award for Best Written Abstract on Urogynecology/Pelvic Floor ...
    Breaking Medicine Technology:Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3
    ... Nov. 9, 2010 As obesity rates and the ... the 2010 mHealth Summit in Washington D.C. is bringing ... discuss the opportunities to address pressing public health issues ... the pioneer in developing wearable body monitoring systems, recently ...
    ... 2010 The clinical practice guideline recently issued by ... spinal compression fractures has left the medical community scratching ... fractures (also called vertebral compression fractures or VCFS) are ... affects an estimated 44 million Americans, or 55 percent ...
    Cached Medicine Technology:Results of Two New Clinical Studies Show Promise of Emerging Mobile Health Technology to Combat Obesity Epidemic 2Results of Two New Clinical Studies Show Promise of Emerging Mobile Health Technology to Combat Obesity Epidemic 3AAOS Clinical Guideline for Treating Spinal Compression Fractures Presents More Questions Than Answers for Medical Community 2AAOS Clinical Guideline for Treating Spinal Compression Fractures Presents More Questions Than Answers for Medical Community 3
    (Date:11/22/2014)... (HealthDay News) -- A clinical trial of hydroxyurea therapy ... a year early because the results show it is ... and reduce the risk of stroke. The announcement ... centers in the United States and Canada, was made ... Blood Institute (NHLBI). Researchers compared monthly blood transfusions ...
    (Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. 21, 2014 (HealthDay ... in an ambulance by a neurologist equipped with a CT ... patients get the clot dissolver -- tissue plasminogen activator (tPA) ... noted. For the best outcome, the drug needs to be ... researchers said. "The so-called ,golden hour, is associated with ...
    (Date:11/21/2014)... CT (PRWEB) November 21, 2014 CRN ... a veteran radio industry sales professional to its award-winning ... brings 30 years of leadership and sales experience to ... and assume the title of Director of Strategy and ... Development, Robert O’Mara. , Heinemann will handle a wide ...
    (Date:11/21/2014)... to make it tougher for people to misuse prescription ... approved a new hydrocodone tablet that,s designed to help ... brand name Vicodin -- is a powerful opioid painkiller ... addictions across the United States. The FDA said ... extended-release tablet to treat pain severe enough to require ...
    (Date:11/21/2014)... they,ve mapped the genome -- the genetic "blueprint" -- of ... it might help others with this very rare infection. ... , the tapeworm was removed from the brain of a ... so rare worldwide and completely unexpected in this country that ... pulled out from the brain," study lead author Hayley Bennett, ...
    Breaking Medicine News(10 mins):Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2
    ... cancer research. They say they have been able to grow cancer ... of cancer treatments, they hope. ,Liu Hua, a visiting ... had for years been able to grow cancer cells in laboratories, ... that doctors to whom he showed the tumour he had developed ...
    ... have shown in a laboratory study that revving up ... caused by a form of muscular dystrophy. ... Development, the researchers demonstrated that manipulating a genetic molecular ... mice with Duchenne muscular dystrophy, slowing the disease-associated muscle ...
    ... U.S. Food and Drug Administration (FDA) today announced that ... treat Parkinson’s disease, will voluntarily remove// these drugs from ... to patients’ heart valves. ,The products being ... by Valeant Pharmaceuticals, and two generic versions of pergolide ...
    ... in the development of vaccines for bird flu, clearly revolves ... bird flu, the H5N1 virus, which could mutate to pandemic ... the world have continually exchanged information with the WHO on ... of assisting scientists to be abreast with the genetic composition ...
    ... fellow scientists in Japan have developed a new system that ... to smog// and high ozone levels. ,Many volatile ... oxides, contribute to smog and ozone levels and are potentially ... ,Anil K. Sinha at the Toyota Central R&D Labs ...
    ... wake of persistent supply shortage, the World Health Organisation has ... undesirable practice of preying upon poorer nations by patients from ... transplants far exceeds supply, WHO said after a meeting of ... most sought-after organ with the 66,000 transplanted in 2005. That ...
    Cached Medicine News:Health News:Switching Genes to Overdrive Improves Muscular Dystrophy Symptoms in Mice 2Health News:FDA Announces Voluntary Withdrawal of Pergolide Products 2Health News:Transplant Tourism on the Rise, Says WHO 2
    Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
    ... of Type III Laboratory-grade Water, RiOs reverse ... to 8000 L/day of Type III laboratory-grade ... Purification and Control Unit, RiOs systems can ... total control of all parameters within the ...
    ... produce Type III, laboratory-grade pure water at ... directly with potable tap water and combine ... design that is easy to operate, reliable, ... produced at a low operating cost., Applications, ...
    ... Ultra Low Freezers -85C offer efficiency and ... Compressor life is extended by an energy-saving ... constant flow of refigerant. Heat is efficiently ... with three fans. Monitoring light to warn ...
    Medicine Products: